Stifel Keeps Inovio Pharma (INO) at 'Buy' Following Q1 Report; Cash Position Expected to Remain Firm on New Grants
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- Wall Street ends lower, off record highs, as Treasury yields climb
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Chip stock could soar nearly 200%, analyst says: "If you don’t buy it, they will"
- Musk rules out TSMC role in Terafab operations; Intel gains
| INOVIO PHARMACEUTICALS, Inc. (NASDAQ: INO) | Delayed: 1.16 +0.03 (2.65%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.13 | 52 Week High | $11.69 | |||
| Open | $1.12 | 52 Week Low | $4.50 | |||
| Day High | $1.19 | P/E | N/A | |||
| Day Low | $1.11 | EPS | $-0.28 | |||
| Volume | 2,796,762 | |||||
